MVK activates microglia and decreases phagocytosis. by Ren Y. Sato (16914027)

Average difference in mean daily exercise minutes in the week before and after the specified software transition, using different minimum data thresholds. by Shelby L. Sturrock (10751675)

Subjects: “…statistically significant decreases…”

Average difference in mean daily active calories in the week before and after the specified software transition, using different minimum data thresholds. by Shelby L. Sturrock (10751675)

Subjects: “…statistically significant decreases…”

Full-length PRR expression increases and sPRR secretion decreases in the absence of PACE4 in mouse. by Amro H. Mohammad (15081540)

Naringenin decreases total cell viability. by Lauren A. Eanes (20995499)

Standardised mean differences (SMD) before and after applying inverse probability weighting. by Camilla Pegram (11938584)

Changes in mean end-expiratory diaphragm thickness over time during mechanical ventilation in each group. by Taiga Itagaki (8069489)

Median EQ-5D-3L index values during 5 years of follow-up. by Karl Ingard (22582091)

The forest plots of pooled estimates of standardized mean differences of circulating apelin (A), apelin/HDL-c (B), apelin/LDL-c (C), apelin/triglycerides (D), and apelin/total chol... by Hamed Akbari (8119361)

Subjects:

Port-sourced PM_2.5 (μg/m³) concentrations 2017 at the Barcelona neighbourhood level. by Natalie Mueller (3406370)

Subjects:

List of Included studies. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

The search strategy in three databases. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

A summary of the included study characteristics. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

NIH score. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

List of excluded studies. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

Individual and mean EQ-5D VAS scores in the PP-group (0 = baseline, 1 = after the first day of treatment, 2 = after the second day of treatment, 3 = after the third day of treatmen... by Marcus Persson (20496333)

Fig 1 - by Denise Wajnsztajn (3366902)

Subjects:

Comparison of Delta Kmax and Delta LogMAR with different crosslinking protocols analyzed with ANOVA (p<0.001). by Denise Wajnsztajn (3366902)

Subjects:

Delta Kmax¹ with non-accelerated and accelerated CXL² protocols. by Denise Wajnsztajn (3366902)

Subjects:

Multivariate analysis of variables affecting Delta Kmax. by Denise Wajnsztajn (3366902)

Subjects: